Catalent To Discuss How Drug Design Influences Patient Outcomes At PODD

SOMERSET, N.J. – October 2, 2019 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it will present at the 9th Partnership Opportunities in Drug Delivery (PODD) annual conference at the Renaissance Boston Waterfront Hotel, Boston, on Oct. 7 – 8, 2019.

On Tuesday, Oct. 8 at 1:20 p.m., Cornell Stamoran, Ph.D., Founder and Co-Chair of the Catalent Applied Drug Delivery Institute, will moderate the “Smart Drug Design and Development – from Candidate to Phase 1” panel during the “Formulations” breakout session. The panel will bring together scientists from industry and academia including Sudhakar Garad, Ph.D., Global Head of Pharmaceutical and Chemical Profiling, Novartis Institutes for Biomedical Research, Keith Horspool, VP of External Alternative CMC Development, Rebecca Carrier Ph.D., Professor, Chemical Engineering, Northeastern University and others. The panelists will explore the key considerations for transitioning a molecule from discovery to clinic and will discuss how every design decision made during this process has the potential to influence patient outcomes.

Dr. Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He has spent nearly 30 years in advanced drug and biologics delivery and outsourcing. Dr. Stamoran founded the Catalent Applied Drug Delivery Institute ( in 2012 to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery.

For more information, please visit

To arrange a meeting with Dr. Stamoran or any of the attending Catalent experts at the event, contact Richard Kerns at NEPR -

Media Contacts

Chris Halling
+44 (0)7580 041073

Richard Kerns
+44 (0) 161 728 5880

Notes for Editors

About Catalent 

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists, at more than 35 facilities across five continents, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit

More products. Better treatments. Reliably supplied.